

Q3 FY26 Quarterly Activities Report & Appendix 4C

Audeara Ltd (ASX: AUA) ('Audeara' or 'the Company') is pleased to provide the following update for the three month period ended 31 March 2026 ('Q3 FY26').

Highlights

- ▶ Positive net operating cash flows of \$359k for the March quarter marks second consecutive quarter of positive net cash flow
- ▶ YTD positive net operating cash flows now total \$380k compared to a \$928k loss PCP (PCP: Q1-Q3 FY25)
- ▶ Quarterly cash receipts from customers of \$1.54m and \$3.50m year-to-date
- ▶ Unaudited Group revenues¹ of \$1m for the quarter, \$3.9m YTD
- ▶ Strong performance in Australian wholesale, with revenue of \$973k (+75.5% q/q; +103.3% vs PCP)
- ▶ Cash balance of \$1.05m at 31 March 2026 compared to \$734k at 31 December 2025

Financial results underpinned by strong operational momentum:

- ▶ Continued strength in Australian wholesale channel, with improved order cycles supporting revenue conversion
- ▶ Auracast™ platform expansion underway with Clinico Inc., including initial purchase orders and continued progression of white-label programs
- ▶ Auracast device sales expanded to include distributors in Japan, USA and Australia with negotiations underway for European and Asian market expansion

Outlook:

Audeara remains focused on:

- ▶ Maintaining positive operating cash flow
- ▶ Strengthening Australian wholesale performance
- ▶ Converting AUA Technology partnerships into recurring revenue streams

¹ All references to revenues in FY26 are unaudited revenues.



Management commentary

Audeara CEO and founder, Dr James Fielding said:

"This quarter marks a clear shift in our cash profile, with a second consecutive quarter of positive operating cash flow, which has underscored a material improvement on the prior year.

Audeara remains focused on scaling its two revenue generating engines — a wholesale channel that drives near-term cash generation, and a technology platform that is designed to scale globally through licensing. Both are delivering strong results, but both also introduce timing variability in the short term.

Pleasingly, the Company is achieving increasing demand across wholesale and meaningful progress in the AUA Technology programs, including Auracast™ and partner-led initiatives. This outlook provides us with a clear line of sight to capture growth in the coming months and to begin delivering at scale.

As we deliver this scale, we expect contributions from AUA Technology to increase meaningfully beyond our cost effective engineering investments, while wholesale continues to underpin commercial operations. That is the inflection point for the business — and we are moving toward it with increasing momentum."

Financial overview

Audeara recorded cash receipts from customers of \$1.542 million for Q3 FY26 and \$3.503 million year-to-date.

Net operating cash flow for the quarter was positive \$359,000, which takes total positive net cash to \$380,000 year-to-date. This represents a significant improvement compared to the prior corresponding period, where March quarter year-to-date operating cash flow reflected a \$928,000 outflow.

Operating cash flow for the quarter reflects:

- ▶ Strong customer receipts
- ▶ Timing of inflows from key customers
- ▶ Active management of supplier payments

Payments during the quarter included:

- ▶ Research and development: \$109k
- ▶ Product manufacturing and operating costs: \$341k
- ▶ Staff costs: \$521k




- ▶ Administration and corporate costs: \$176k
- ▶ Payments to related parties including directors' fees were \$116k, in line with Q2 FY26.

Cash Position


- ▶ Cash and cash equivalents at 31 March 2026 were \$1.050 million, compared to \$734k at 31 December 2025. The increase in cash position reflects positive operating cash flow achieved during the quarter.

Quarterly Cash Receipts vs. Net Operating Cash Flow






Annual Cash Receipts vs. Net Operating Cash Usage



Annual Revenue





Operational Overview – Quarterly Highlights

ShokzHear – Product Development & Commercial Progress

During the quarter, Audeara continued to progress its working relationship and product refinement with ShokzHear as announced 23 October 2025.

Development activities remain focused on:

- ▶ Optimisation of open-ear listening performance utilising Audeara's expertise
- ▶ Preparation for commercial deployment within defined channel strategies

The program is progressing toward its next commercial milestone, with:

- ▶ Product development advancing in line with partner requirements
- ▶ Ongoing alignment with channel and go-to-market strategy
- ▶ Preparation for initial commercial rollout activities

A ShokzHear product for the Australian market represents a key opportunity to expand Audeara's presence in the open-ear and health-focused listening devices market segment, leverage Shokz's global brand and expertise and deliver an additional, scalable, partner-led revenue channel through integrated technology offerings.

Australian Wholesale Channel

Audeara demonstrated continued strength in its Australian wholesale business during the period, underpinned by repeat orders from its largest customer base.

In late November, the Company secured a record \$560,000 purchase order from a major Australian wholesale customer – the largest single wholesale order in Audeara's history. The order was recognised as revenue in the March 2026 quarter and cash receipts were also recognised.

Current YTD sales of \$2.24m are already a 25% increase on full year FY25 Australian wholesale revenue with the release of the new Auracast portfolio into major national key accounts creating a solid platform for continued growth.

Auracast™ Platform Expansion – Clinico Inc.

During the quarter, Audeara announced the expansion of its Auracast™ platform with Clinico Inc.

The program includes:

- ▶ Progression of multiple white-label product programs
- ▶ Initial purchase orders to commence production



- ▶ Integration of Audeara's broadcast and personalised listening technology into partner-led products

This initiative supports the continued rollout of AUA Technology through scalable, partner-driven channels.

China Market Update – Strategy Optimisation Underway

Following the successful NMPA certification and initial market testing with our partner in China, the focus during the quarter has shifted to refining and optimising the go-to-market strategy.

Our partner is currently undertaking a strategic review to ensure the most effective launch and scaled commercialisation of the personalised hearing product across China's primary e-commerce and online healthcare platforms.

While this process has meant that significant commercial traction is in a build-up phase, the initial market testing completed during the quarter has provided valuable insights which are being integrated into the refined strategy. The Company remains confident in the substantial long-term growth opportunity in this major market, and the pathway established through our capital-light licensing model. We anticipate the results of the optimised strategy to drive commercial sales momentum in the coming quarters.

AUA Technology – AI & Licensing Expansion

Chip-level AI audio licensing agreement with Optek Microelectronics:

Audeara's AUA algorithms, including AI Noise Reduction and Media Personalisation, are now being embedded directly into Optek's system-on-chip platforms. This integration enables a royalty-style revenue stream on a fee-per-chip basis across global OEM and ODM programs. Initial capability demonstrations are scheduled for SuHi Tech in late April. This represents a significant technology step toward scaling the business.

Japan – Auracast™ Technology platform expansion

During the quarter, Audeara received follow on orders from its Japanese distributor and was selected to join the Trade and Investment Queensland (TIQ) health innovation trade mission to SusHi Tech Tokyo 2026, Asia's largest global innovation conference. Attending from Apr 27 to Apr 29, 2026, the company will showcase its advanced assistive listening solutions—including its pioneering Auracast™ broadcast technology—to over 60,000 participants and 1,700 venture capitalists and investors. This mission provides a high-impact platform to engage directly with industry leaders from Japan and surrounding Asia-Pacific markets, focusing on key thematic areas of AI, resilience, and entertainment. The program includes a dedicated pitch session on the event's main stage and targeted business matching to accelerate Audeara's strategic expansion and partnership opportunities within the Japanese technology ecosystem.

Outlook

Audeara remains focused on:

- ▶ Maintaining positive operating cash flow



- ▶ Strengthening Australian wholesale performance
- ▶ Converting AUA Technology partnerships into recurring revenue streams

The Company enters the final quarter of FY26 with improved cash flow dynamics and continued execution across its commercial channels.

This announcement has been authorised by the Board of Audeara Limited.

For more information please visit, audeara.com.

CORPORATE & MEDIA ENQUIRIES

Dr James Fielding

Managing Director and Chief Executive Officer

james.fielding@audeara.com

INVESTOR ENQUIRIES

Henry Jordan

Six Degrees Investor Relations

henry.jordan@sdir.com.au

ABOUT AUDEARA

Feel connected, your way.

Audeara Limited (ASX: AUA) is a global hearing health leader specialised in innovative listening solutions for people with hearing challenges.

We are passionate about redefining hearing health, with a particular focus on delivering products that provide world-class tailored listening experiences.

We care about connecting people with experiences that bring them joy - whether that's watching a favourite TV show, FaceTiming family or listening to music with confidence.

All Audeara products are purposefully designed and engineered in Australia with precision detail and state-of-the-art technology. Each product delivers optimum listening experiences to enhance quality of life for people of all ages and abilities.

Audeara sells its products through distributors and resellers in Australia, Europe, Asia and North America, and through e-commerce channels.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AUDEARA LIMITED

ABN

27 604 368 443

Quarter ended ("current quarter")

31 MARCH 2026

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
1	Cash flows from operating activities		
1.1	Receipts from customers	1,542	3,503
1.2	Payments for		
(a)	research and development	(109)	(383)
(b)	product manufacturing and operating costs	(341)	(1,516)
(c)	advertising and marketing	(50)	(166)
(d)	leased assets	(1)	(2)
(e)	staff costs	(521)	(1,692)
(f)	administration and corporate costs	(176)	(639)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	1	10
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	14	1,265
1.8	Other (provide details if material)	-	-
1.9	Net cash from / (used in) operating activities	359	380
2	Cash flows from investing activities		
2.1	Payments to acquire or for:		
(a)	entities	-	-
(b)	businesses	-	-
(c)	property, plant and equipment	(4)	(13)
(d)	investments	-	-
(e)	intellectual property	-	-
(f)	other non-current assets	-	-
2.2	Proceeds from disposal of:		
(a)	entities	-	-
(b)	businesses	-	-
(c)	property, plant and equipment	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
(d)	investments	-	-
(e)	intellectual property	-	-
(f)	other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(4)	(13)

3	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	418
3.6	Repayment of borrowings	(35)	(1,049)
3.7	Transaction costs related to loans and borrowings	(1)	(110)
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(36)	(741)

4	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	734	1,422
4.2	Net cash from / (used in) operating activities (item 1.9 above)	359	380
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(4)	(13)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(36)	(741)
4.5	Effect of movement in exchange rates on cash held	(3)	2
4.6	Cash and cash equivalents at end of period	1,050	1,050

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

5 Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	1,050	734
5.2 Call deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,050	734

6 Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1 Aggregate amount of payments to related parties and their associates included in item 1	116
6.2 Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>	

7 Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	418	418
7.2 Credit standby arrangements	-	-
7.3 Other (insurance premium funding)	-	-
7.4 Total financing facilities	418	418
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
7.1: Short term loan facility with Sturt Capital Pty Ltd against the anticipated R&D Tax Incentive rebate for FY2026 Q1 & Q2. The loan facility has an establishment fee of 1.5%, bears interest of 1.33% per month with a repayment date which is earlier of the date of receipt of the 2026 R&D Tax Incentive from the Australian Taxation Office and 31 December 2026. Principal outstanding at 31 March 2026 was \$417,876.		

8 Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	359
8.2 Cash and cash equivalents at quarter end (item 4.6)	1,050
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	1,050
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 14 April 2026

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.